



Review

# Extracellular matrix regulation of inflammation in the healthy and injured spinal cord



Andrew D. Gaudet\*, Phillip G. Popovich\*\*

Center for Brain and Spinal Cord Repair, Department of Neuroscience, College of Medicine, The Ohio State University, 670 Biomedical Research Tower, 460 West 12th Ave., Columbus, OH 43210, USA

ARTICLE INFO

*Article history:*  
 Received 18 October 2013  
 Revised 18 November 2013  
 Accepted 19 November 2013

*Keywords:*  
 Neuroinflammation  
 Immune  
 DAMP  
 Toll-like receptors  
 TLR  
 Hyaluronan  
 Tenascin  
 Proteoglycan

ABSTRACT

Throughout the body, the extracellular matrix (ECM) provides structure and organization to tissues and also helps regulate cell migration and intercellular communication. In the injured spinal cord (or brain), changes in the composition and structure of the ECM undoubtedly contribute to regeneration failure. Less appreciated is how the native and injured ECM influences intraspinal inflammation and, conversely, how neuroinflammation affects the synthesis and deposition of ECM after CNS injury. In all tissues, inflammation can be initiated and propagated by ECM disruption. Molecules of ECM newly liberated by injury or inflammation include hyaluronan fragments, tenascins, and sulfated proteoglycans. These act as “damage-associated molecular patterns” or “alarmins”, i.e., endogenous proteins that trigger and subsequently amplify inflammation. Activated inflammatory cells, in turn, further damage the ECM by releasing degradative enzymes including matrix metalloproteinases (MMPs). After spinal cord injury (SCI), destabilization or alteration of the structural and chemical compositions of the ECM affects migration, communication, and survival of all cells – neural and non-neural – that are critical for spinal cord repair. By stabilizing ECM structure or modifying their ability to trigger the degradative effects of inflammation, it may be possible to create an environment that is more conducive to tissue repair and axon plasticity after SCI.

© 2013 Elsevier Inc. All rights reserved.

Contents

Introduction . . . . .	25
SCI-induced inflammation: An overview . . . . .	25
Composition and functions of ECM in the healthy and inflamed CNS . . . . .	26
Hyaluronan: From scaffolding champ to damaging DAMP . . . . .	26
Hyaluronan in healthy spinal cord . . . . .	26
HA and inflammation: Implications for SCI repair . . . . .	26
Decreasing DAMPs: Hyaluronan modulation as a potential SCI treatment . . . . .	28
Sulfated proteoglycans . . . . .	28
Sulfated proteoglycans in the healthy spinal cord . . . . .	29
Sulfated proteoglycans and inflammation: Implications for SCI repair . . . . .	29
Plasticity unleashed: Sulfated proteoglycan modulation as a potential SCI treatment . . . . .	29
Tenascins: Promiscuous proteins weave a complex narrative . . . . .	30
Tenascins in the healthy spinal cord . . . . .	30
Tenascins and inflammation: Implications for SCI repair . . . . .	30
Tailored tenascin targeting: Potential as an SCI treatment . . . . .	31
Conclusions & implications . . . . .	31
Acknowledgments . . . . .	31
References . . . . .	31

\* Correspondence to: A.D. Gaudet, Center for Brain and Spinal Cord Repair, Department of Neuroscience, The Ohio State University, 670 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH 43210, USA.

\*\* Corresponding author.

E-mail addresses: [andrew.gaudet@osumc.edu](mailto:andrew.gaudet@osumc.edu) (A.D. Gaudet), [phillip.popovich@osumc.edu](mailto:phillip.popovich@osumc.edu) (P.G. Popovich).

## Introduction

Tissue damage triggers inflammation and degradation of the extracellular matrix (ECM).<sup>1</sup> The ECM is an intricately arranged scaffold comprised of secreted proteins and complex sugars that together support cell function and survival. After injury, the ECM is degraded and the composition changes. Some ECM molecules become aberrantly expressed, whereas others are cleaved into bioactive fragments known as damage-associated molecular patterns (DAMPs) or “alarmins”. Through their ability to bind to different types of pattern recognition receptors (PRRs), these ECM molecules can influence the phenotype and magnitude of inflammation (Bianchi, 2007; Piccinini and Midwood, 2010; Kigerl et al., 2014-in this issue) but see (Erridge, 2010). Moreover, the enzymes and inflammatory mediators released by immune cells further degrade or alter the composition of the ECM.


Remarkably little is known regarding the relationship between ECM and neuroinflammation, especially in the context of SCI (Fig. 1). Intentionally altering the composition of the lesion ECM could influence inflammatory cell signaling and subsequent release of cytokines or growth factors that affect mechanisms of CNS repair. Conversely, targeting inflammatory cells directly could “improve” the composition of the ECM, favoring a mixture of molecules that permit axon growth or that suppress the harmful effects of inflammation.

In this review, interactions between the ECM and the immune system are highlighted. First, a brief overview of SCI-induced inflammation is provided followed by a detailed discussion of the ECM in the healthy CNS and the potential implications for enhanced ECM: immune cell interactions in the inflamed CNS. Several key ECM molecules are considered, with a focus on how they affect inflammation. Finally, potential strategies for manipulating ECM:immune cell interactions are discussed in the context of improving recovery after SCI.

### SCI-induced inflammation: An overview

Injury to the spinal cord elicits an inflammatory response that, at least in its early stages, is remarkably similar to that initiated by injury elsewhere in the body (Popovich and Longbrake, 2008). Blood–spinal cord barrier breakdown occurs soon after injury leading to progressive hemorrhagic necrosis at the lesion epicenter (Noble and Wrathall, 1989; Popovich et al., 1996; Schnell et al., 1999; Simard et al., 2007, 2010). Blood-derived immune cells (leukocytes) invade the spinal cord in waves, regulated in part by newly-formed ECM molecules that act as chemoattractants. Neutrophils accumulate within 24 hpi, reaching maximal levels 3–14 dpi (Fleming et al., 2006; Kigerl et al., 2006; Stirling and Yong, 2008). Monocytes infiltrate 1–2 dpi with peak accumulation occurring ~7–14 dpi. Monocytes differentiate into macrophages that persist indefinitely at the lesion site (Kigerl et al., 2006, 2009; Popovich et al., 1997). In the pathological spinal cord, both neutrophils and macrophages adopt an inflammatory phenotype and release soluble factors, including cytokines, proteolytic enzymes and oxidative metabolites, that exacerbate injury. A unique feature of inflammation

<sup>1</sup> Abbreviations: ADAM: a disintegrin and metalloproteinase; ADAM-TS: a disintegrin and metalloproteinase with thrombospondin motif; CCL: CC chemokine ligand; chABC: chondroitinase ABC; CNS: central nervous system; CS: chondroitin sulfate; CS-A: chondroitin sulfate-A; CSPG-DS: disaccharide CSPG product; CXCL: CXC chemokine ligand; DAMP: damage-associated molecular pattern; dpi: days post-injury; DS: dermatan sulfate; EAE: experimental autoimmune encephalomyelitis; ECM: extracellular matrix; GAG: glycosaminoglycan; GPI: glycosphosphatidylinositol; HA: hyaluronan; HMW-HA: high molecular weight hyaluronan; hpi: hours post-injury; HS: heparan sulfate; IL–: interleukin–; KO: knockout; KS: keratan sulfate; LMW-HA: low molecular weight hyaluronan; MMP: matrix metalloproteinase; MT-MMPs: membrane-bound metalloproteinases; PG: proteoglycan; PNS: peripheral nervous system; PRR: pattern recognition receptor; SLRP: small leucine-rich repeat protein; TGF: transforming growth factor; TIMP: tissue inhibitors of metalloproteinases; TLR: Toll-like receptor; TNF: tumor necrosis factor; TSP: thrombospondin.



**Fig. 1.** Limited research publications exist with a focus on understanding the interactions between inflammation, SCI, and ECM (red area). Searches were performed on PubMed for the words “inflammation”, “spinal cord injury”, and “extracellular matrix”, alone and in combination (as of September 2013). “Inflammation” returned ~418,000 results; “spinal cord injury” ~50,000, and “extracellular matrix” ~80,000. However, when a search combined all three terms, only 19 results were returned. Sizes of circles and overlaps are proportional to the total number of citations returned for each search (Venn diagram constructed using eulerAPE). In the context of SCI and its relationship to inflammation and ECM, vast expanses of knowledge remain to be discovered.

in the injured spinal cord (or brain) is that this response persists indefinitely, i.e., there is no resolution phase of inflammation in injured spinal cord and chronic waves of leukocyte recruitment occur (Beck et al., 2010; Kigerl et al., 2006, 2009; Pajoohesh-Ganji and Byrnes, 2011; Pruss et al., 2011). Chronic inflammation has adverse consequences, including fibrosis (the deposition of excess connective tissue) and impaired tissue healing (Diegelmann and Evans, 2004; Nathan and Ding, 2010). Accordingly, controlling inflammation holds promise for improving CNS repair. How to accomplish this is less obvious. On the one hand, methods to deplete or inhibit leukocyte functions can be neuroprotective and improve recovery, especially if the intervention is started early after trauma (Berli et al., 2007; Blight, 1994; Busch et al., 2009; Eng and Lee, 2003; Giulian and Robertson, 1990; Gris et al., 2004; Noble et al., 2002; Popovich et al., 1999). However, these same cells can enhance repair and disrupting the normal composition or dynamics of acute inflammation could have unwanted long-term consequences (Rapalino et al., 1998; Shechter and Schwartz, 2013; Stirling et al., 2009).

Cells intrinsic to the spinal cord also contribute to SCI-induced inflammation. Microglia and astrocytes near the lesion become activated, proliferate, and release inflammatory cytokines (Bartholdi and Schwab, 1997; Brambilla et al., 2005; Pineau et al., 2010; Popovich et al., 1997). In addition, astrocytes adjacent to the lesion form a matrix-rich glial scar, which limits the extent of hemorrhagic damage and leukocyte migration but also restricts axon plasticity (Alilain et al., 2011; Bradbury et al., 2002; Faulkner et al., 2004; McKeon et al., 1991; Wanner et al., 2013).

A novel approach for controlling inflammation might be to manipulate the ECM. The ECM can regulate inflammation by: (1) releasing DAMPs or alarmins that influence inflammatory cell activation via PRRs (also see Kigerl et al., 2014-in this issue for a detailed review of PRR-mediated regulation of innate immunity in the injured CNS); (2) sequestering or presenting growth factors, cytokines, and chemokines (chemoattractant cytokines); and (3) affecting inflammatory cell migration (Gill et al., 2010). Altering the ECM in a manner that promotes an anti-inflammatory or immune modulatory response and decreases glial scar formation could improve tissue preservation and increase axon sprouting.

## Composition and functions of ECM in the healthy and inflamed CNS

About 20% of the total volume of the adult CNS is extracellular space (Bignami et al., 1993) that contains highly organized ECM (see Hynes and Naba, 2012). As in peripheral tissues, the ECM is composed of interstitial and basement membrane ECM; however, in the CNS the ECM composition is remarkably different. Whereas interstitial ECM of most tissues is enriched in collagen, laminin, and fibronectin, the ECM of adult CNS is primarily a loose meshwork of hyaluronan (HA), sulfated proteoglycans (PGs), and tenascin-R (Lau et al., 2013; Rauch, 2007). Unique high-density ECM aggregates called perineuronal nets (PNNs) also form around neuronal soma and dendrites. PNNs assemble during development and act to restrict synaptic plasticity and aberrant axon sprouting (Galtrey et al., 2008; Garcia-Alias and Fawcett, 2012). The significance of the PNN after SCI has been considered in recent reviews (Dityatev et al., 2010; Wang and Fawcett, 2012) and is beyond the scope of the current review. Instead, this review will focus on SCI-induced changes to the interstitial ECM and the inflammatory consequences of those changes.

The major components of the interstitial ECM in healthy CNS are HA, sulfated PGs, and tenascin-R. The interactions between fibronectin domains on tenascin and lectin domains on hyalactans, combined with hyalactan binding to hyaluronan, create massive, stable ECM complexes (Fig. 2). HA, the most prevalent ECM component, is a unique glycosaminoglycan (GAG) (Laurent and Fraser, 1992); GAGs are long unbranched chains of repeating disaccharides. Unlike other GAGs, HA is unsulfated and is not generally associated with a core protein. HA polymers are unusually large (MW > 1000 kDa) and because they displace large volumes of water, they absorb forces well and are excellent lubricants (Tammi et al., 2002). In healthy tissue, this high molecular weight (HMW)-HA constitutes the framework for the structure of the CNS, as other ECM components like sulfated PGs can bind and cross-link HMW-HA (Hardingham and Fosang, 1992; Hardingham and Muir, 1972; Knudson and Knudson, 1993).

Sulfated PGs consist of a protein core that is covalently linked to one or more sulfated GAG chains. PGs can be categorized based on distinct properties of their core proteins, sulfation patterns, location, size, or modular composition. In general, there are three major categories of sulfated PGs: modular, cell-surface, and small leucine-rich repeat PGs (Schaefer and Schaefer, 2010). Modular PGs have multiple protein domains and are often elongated and highly glycosylated. Modular PGs are major constituents of the healthy CNS ECM, and can be further divided into HA-binding (hyalactans) and non-HA binding (mainly basement membrane PGs). The hyalactan aggrecan is particularly enriched in the CNS and forms large aggregates with HA (Rauch, 2004). Cell-surface PGs can be transmembrane or glycosphosphatidylinositol-linked and are involved in cell signaling. Examples include NG2, RPTP- $\rho$ , syndecan, and glypican (also see Shen; this issue for a detailed review of how PGs and other regeneration associated molecules influence intraspinal inflammation). Small leucine-rich repeat PGs (SLRPs), including decorin and biglycan, participate mainly in protein–protein interactions and have diverse functions (Moreth et al., 2012).

Another CNS ECM component is tenascin-R, a protein that forms homodimers or trimers (Norenberg et al., 1996). Tenascin-R binds to lectin-like domains on hyalactans (Aspberg et al., 1997). In this manner, HA-hyalactan aggregates can be cross-linked to form a super-structure that provides a contiguous, stable substrate for cells and extracellular molecules (Fig. 2).

After SCI, key components of the intact ECM are degraded (e.g., HA), while other components are newly expressed (e.g., tenascin-C) (Fig. 2b). These latter molecules act as DAMPs that propagate inflammation, which subsequently causes further ECM degradation and remodeling. This feed-forward loop could be responsible for propagating chronic inflammation after SCI (Fig. 3).

In all tissues, matrix metalloproteinases (MMPs) comprise a key intermediary between inflammation and the degradation or remodeling of ECM (Yong, 2005). MMPs are zinc-dependent endopeptidases that modify the ECM and other proteins including cytokines and cell surface receptors (Malemud, 2006). During inflammation, MMP activity is increased by fragmented HA (Sugahara et al., 2003; Yong and Guoping, 2008). In turn, increased MMP activity liberates ECM-derived DAMPs, including sulfated PGs (Brule et al., 2006) and tenascin fragments (Siri et al., 1995). MMP-evoked inflammation is likely detrimental to SCI repair; both MMP-9 and MMP-12 have been shown to limit recovery (Hansen et al., 2013; Hsu et al., 2008; Noble et al., 2002; Wells et al., 2003). The role of MMPs in tissue pathology and recovery after SCI has been reviewed elsewhere (Agrawal et al., 2008; Yong, 2005; Yong et al., 2007; Zhang et al., 2011). The remainder of this review focuses on the three major interstitial ECM components in the CNS: hyaluronan, sulfated PGs, and tenascins.

## Hyaluronan: From scaffolding champ to damaging DAMP


Though its structure is simple, HA has remarkable properties. HA's viscosity and its ability to retain water underlie its critical functions in homeostasis and tissue integrity: HA acts as a scaffold that creates and maintains multivalent extracellular interactions between ECM molecules. HA is produced intracellularly by HA synthases (HAS1-3) and is released through plasma membrane pores into the ECM (Watanabe and Yamaguchi, 1996; Weigel et al., 1997). Extracellular HA interacts with several membrane receptors/proteins, including CD44, HA synthase, TLR-2 and -4, ICAM-1, and receptor for HA-mediated mobility (RHAMM) (Aruffo et al., 1990; Hardwick et al., 1992; Jiang et al., 2005; Jiang et al., 2007; McCourt et al., 1994; Turley et al., 2002).

### *Hyaluronan in healthy spinal cord*


In the healthy spinal cord, HMW-HA (MW > 1000 kDa) is the major HA form (Struve et al., 2005). HA is released into the extracellular space, mainly by astrocytes, and then becomes localized around astrocytes, myelinated axons, and neuron cell bodies (Bignami and Asher, 1992; Eggl et al., 1992; Struve et al., 2005). HMW-HA decreases inflammatory signaling in cultured microglia, likely by blocking the ability of extracellular ligands to bind innate immune receptors (Austin et al., 2012). For example, because CD44 and TLR-4 exist in a receptor cluster, HMW-HA binding to CD44 could block LPS/TLR-4 interactions on the surface of microglia. In cultured astrocytes, HMW-HA reduces proliferation and CSPG deposition (Khaing et al., 2011). Given that various TLR-stimulating DAMPs are released after SCI, exogenous HMW-HA could be introduced into the lesion to restrict inflammation and reduce glial scarring.

### *HA and inflammation: Implications for SCI repair*

As a result of injury, HMW-HA becomes fragmented, creating a pool of low-molecular weight (LMW)-HA (<200 kDa) that can amplify inflammatory responses (Jiang et al., 2007). Inflammation-induced fragmentation, mediated in part through the release of enzymes including hyaluronidases and MMPs or reactive oxygen species also destabilizes the ECM (Esser et al., 2012; Hrabarova et al., 2011) (Fig. 2). In contrast to the immune inert HMW-HA, LMW-HA is a DAMP that initiates inflammatory signaling in macrophages or microglia culminating in elevated expression of inflammatory cytokines (e.g., MIP-1 $\alpha$ , CCL-2, IL-12, and TNF- $\alpha$ ), iNOS, and matrix-modifying enzymes (Collins et al., 2011). LMW-HA is also a potent macrophage and neutrophil chemoattractant (Jiang et al., 2005). LMW-HA elicits responses from inflammatory, but not unstimulated macrophages or monocytes (Brown et al., 2001; Levesque and



**Fig. 2.** (a) Major interstitial ECM components in the healthy CNS. The massive non-sulfated GAG hyaluronan (HA) is the most prominent structural component of CNS ECM. Aggrecan (CS/KSPG) and tenascin-R are also enriched in healthy ECM. The three types of PGs are hyaluronan-binding hyalectans, small leucine-rich repeat proteins (SLRPs), and cell surface PGs. GAGs (including HA) are green and are shown attached to thicker core proteins (shades of blue). The N-terminal of the hyalectans aggrecan, versican, neurocan, and brevican binds to HA with assistance from link proteins (pink circles). Small leucine-rich repeat proteins (SLRPs) exist in the extracellular space and participate in important protein–protein interactions. Cell surface PGs contain transmembrane domains or can be GPI-linked to the membrane. Some cell-surface PGs can also be released extracellularly by proteolytic processing (not shown). CD44 containing the v3 domain can bind HS or CS GAG (shown). The ECM protein tenascin-R, which exists as a dimer or trimer, can bind a lectin-like domain on the C-terminal of hyalectans. The HA–hyalectan–tenascin interactions likely underlie ECM scaffold development and maintenance in CNS ECM. Size of molecules in image approximates actual relative size (except HA, which is much longer than depicted) and GAG chain composition. Schematic is not representative of the relative abundance of these molecules in healthy CNS. Tenascin-C (gray) is not highly expressed in the healthy CNS; however, it is important after SCI. Small gray lines on cell surface PGs represent intramolecular disulfide bonds. (b) Model of ECM molecular interactions that contribute to scaffolding and structure adult CNS, before injury (left) and after injury (right). Massive HMW-HA GAG chains fill space and provide binding sites for hyalectans. The CS/DSPG aggrecan is particularly enriched in the healthy CNS, and forms large aggregates on HA GAGs. Tenascin-R interaction with lectin-like domains on hyalectans could link neighboring HA-based aggregates, creating defined 3D structure and organization of the CNS interstitial ECM. Hyalectans can also exist unbound to HA. After SCI, CNS ECM composition is changed, and its meshwork structure is fragmented. HMW-HA, which is normally ~2000 kDa, is degraded into LMW-HA (<200 kDa). As the most critical structural CNS ECM component, HA degradation causes catastrophic ECM breakdown. Aggrecan is downregulated/degraded after injury; the other hyalectans (brevican, versican, neurocan) are strongly up-regulated for weeks after SCI. Hexameric tenascin-C is aberrantly expressed after SCI and could create new or different molecular interactions, and change steric configurations. SLRPs and the matrix-modifying MMPs are upregulated during inflammation. Size of molecules approximates actual scale.



**Fig. 3.** SCI-induced changes in ECM composition and release of proinflammatory mediators contribute to a vicious feed-forward cycle that exacerbates ECM degradation and inflammation. SCI causes degradation or nascent expression of various ECM molecules. Some of these newly-created ECM molecules act as DAMPs and can activate ECM receptors (including TLRs, integrins, CD44, and RPTPs); others can bind cytokines, chemokines, or growth factors to modulate their presentation to inflammatory cells. Activation of ECM receptors or chemokine/cytokine/growth factor receptors on leukocytes (or astrocytes and microglia) can elicit pro-inflammatory mediator secretion and migration of these cells. Accumulation of activated inflammatory cells contributes to secretion of pro-inflammatory mediators (which are also increased by other SCI-induced mechanisms, like primary trauma and hemorrhagic necrosis). Secreted pro-inflammatory mediators further modify and degrade ECM molecules.

Haynes, 1997; McKee et al., 1996), supporting a role for LMW-HA in propagating active inflammatory cascades.

Using macrophages obtained from TLR2 knockout (KO), TLR4 KO, or MyD88 KO mice, Jiang et al. (2005) found that LMW-HA stimulates inflammatory cytokine production through TLR-2 and TLR-4 via a signaling pathway that requires the adaptor protein MyD88 (see Kigerl et al; 2014-in this issue). After SCI in mice, both TLR-2 and TLR-4 are increased, and are expressed in macrophages/microglia and astrocytes (Kigerl et al., 2007). At 7 days post-SCI, TLR-2 is expressed at similar levels by CD11b+ macrophages and GFAP+ astrocytes, whereas TLR-4 is preferentially expressed by macrophages. Given that SCI causes LMW-HA production and accumulation of TLR-2/4+ cells, LMW-HA represents a DAMP that is readily available in the lesion site with the potential to amplify select inflammatory cascades.

LMW-HA can also regulate inflammation by binding to CD44 expressed on microglia, macrophages, and astrocytes. Treatment of alveolar macrophages with function-blocking CD44 antibody prevented LMW-HA binding and restricted CD44-dependent increases in inflammatory cytokines (McKee et al., 1996). Also, CD44-HA interactions are required for normal neutrophil chemotaxis in response to MIP-2 in vivo (Khan et al., 2004). CD44 can inhibit inflammation by sequestering LMW-HA, thereby limiting its ability to bind TLRs or other PRRs (Kawana et al., 2008; Liang et al., 2007). Also, leukocyte CD44 facilitates LMW-HA internalization and degradation: in CD44 KO mice, bleomycin-induced lung inflammation causes HA to accumulate in the lung, an effect that is abrogated in CD44 KO mice reconstituted with wild-type macrophages (Hollingsworth et al., 2007). Interestingly, LMW-HA injection reduces cytokine release and the sickness behavior caused by injecting LPS into mice; this protective effect was abolished in CD44 KO mice (Muto et al., 2009). These results suggest a potential anti-inflammatory role for LMW-HA-CD44 interactions under specific conditions. Therefore, CD44 has important, yet conflicting roles in regulating inflammatory responses to HA.

The relationship between HA stability/degradation and inflammation could dramatically affect endogenous spinal cord repair. SCI increases CD44 expression (Moon et al., 2004) and LMW-HA formation (Struve et al., 2005). Although the functional significance of

these changes is unknown, they could amplify or propagate post-injury neuroinflammation (see above) and gliosis. Indeed, astrocytes respond to LMW-HA by proliferating and releasing growth-inhibitory CSPGs (Struve et al., 2005). HMW-HA inhibits proliferation of cultured astrocytes, whereas hyaluronidase induces astrocyte cell division.

#### Decreasing DAMPs: Hyaluronan modulation as a potential SCI treatment

Since HMW-HA is a key CNS structural component and is immune inert, stabilizing the GAG or increasing its expression could improve CNS repair (though if simply overexpressed, HMW-HA could be degraded by endogenous inflammatory factors). HMW-HA can be used in bioengineered matrices (e.g., Austin et al., 2012; Gupta et al., 2006; Mothe et al., 2013) and may improve SCI repair, especially when combined with immune regulatory molecules or soluble factors that promote axon growth.

Two studies have reported that application of HA in gel matrices improves recovery in rat SCI models. Implantation of a degradation-resistant HMW-HA hydrogel into a rat dorsal hemisection lesion reduced macrophage/microglial density, gliosis, and CSPG deposition within the first week post-injury (Khaing et al., 2011). In a separate study, Austin et al. (2012) injected hydrogel containing HMW-HA/methyl cellulose intrathecally 24 h after a spinal compression injury. This treatment decreased lesion size, reactive gliosis, and IL-1 $\alpha$  levels, and improved locomotor recovery.

#### Sulfated proteoglycans

Whereas HA is the only exclusively non-sulfated GAG, there are four types of sulfated GAGs: chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate (KS), and heparan sulfate (HS). Sulfated PGs are present throughout the body, but are notably enriched in the CNS (Haddock et al., 2007; Kwok et al., 2008; Sugahara and Mikami, 2007). Different PG core proteins can bind different numbers and combinations of GAG chains (Schaefer and Schaefer, 2010). For example, the SLRP decorin binds a single GAG chain while the hyalactan aggrecan includes up to 100 CS and 30 KS GAG chains. Functional domains on the

core protein also vary and partly define PG function. Most PGs function in the extracellular space or are attached to the plasma membrane (Fig. 2).

#### *Sulfated proteoglycans in the healthy spinal cord*

The hyalactans versican (CS/DSPG), aggrecan (CS/KSPG), neurocan (CSPG), and brevican (CSPG) are expressed in the spinal cord (Jones et al., 2003; Lemons et al., 2003; Tang et al., 2003) (Fig. 2). The hyalactan core proteins have a characteristic three-domain structure, consisting of a central GAG-binding domain, surrounded by an HA-binding N-terminal domain and a lectin-like C-terminal domain (Schaefer and Schaefer, 2010). Through these domains, the sulfated proteoglycans interact with various membrane-bound and ECM ligands. The length of the central protein domain varies between PGs and defines the number of GAG attachment sites (Iozzo, 1998; Wu et al., 2005). Aggrecan, in particular, is enriched in healthy CNS tissue and forms enormous aggrecan-HA aggregates.

Several cell surface PGs are expressed in the healthy CNS, including members of the syndecan and glypican families (both HSPGs) (Ding et al., 2006; Hagino et al., 2003; Properzi et al., 2008). Also, the CSPG NG2 is expressed on oligodendrocyte progenitor cells and macrophages (Jones et al., 2002) (Fig. 2). These sulfated PGs can regulate diverse cellular functions, including adhesion/migration, proliferation, and differentiation.

#### *Sulfated proteoglycans and inflammation: Implications for SCI repair*

Tissue injury frees GAGs from their PG backbone (Taylor and Gallo, 2006). Sulfated PGs and liberated GAGs regulate inflammatory cell responses by directly activating PRRs, by presenting or sequestering cytokines and extracellular proteins, and by modulating inflammatory cell migration (Gill et al., 2010).

PGs and PG fragments liberated by inflammation can bind TLRs or other PRRs. During pulmonary inflammation, HS fragments bind to TLR-4 and augment inflammation (Johnson et al., 2004). Biglycan (CS/DSPG), an SLRP and TLR ligand can be released from the ECM and from activated macrophages to bind TLR-2/-4 (Schaefer and Iozzo, 2008; Schaefer et al., 2005). The hyalactan versican (CSPG) can bind TLR-2/TLR-6 and increase TNF- $\alpha$  expression (Kim et al., 2009). Inflammatory mediators that are elevated or newly expressed can bind intact sulfated PG components to amplify inflammation. In a model of rheumatoid arthritis, binding of complement family members to the lectin domain of aggrecan (intact or fragmented) can sustain inflammation (Melin et al., 2013).

Sulfated PGs can sequester or present chemokines, cytokines, growth factors, and MMPs. Biglycan, decorin (CS/DSPG), and fibromodulin (KSPG) bind transforming growth factor (TGF)- $\beta$  with low affinity (Hildebrand et al., 1994). Decorin-TGF- $\beta$  interactions can alter TGF- $\beta$  intracellular signaling or cause TGF- $\beta$  to become inactivated or sequestered in the ECM (Kolb et al., 2001); all of these scenarios would limit TGF- $\beta$ -mediated glial scar formation and neutrophil chemotaxis. Conversely, the DS chain on decorin can enhance interferon- $\gamma$  and TNF- $\alpha$  signaling (Bocian et al., 2013). Sulfated PGs also can control MMP localization and the ability of the enzyme to activate precursor proteins. For example, PGs can conceal MMP cleavage sites on cytokines, chemokines, and growth factors (Gill et al., 2010; Parks et al., 2004). Therefore, sulfated PGs can fine-tune activity of key bioactive molecules, and inflammation-induced dysregulation of sulfated PG composition or structure can have a long-lasting impact on local cellular dynamics.

Sulfated PGs regulate migration and localization of leukocytes during inflammation (Gotte, 2003; Parish, 2006). GAG-bound chemokines immobilized on the surface of endothelia can be presented to leukocytes in the blood, promoting their transmigration into the inflammatory site. Chemokine-GAG interactions are highly

specific, providing exquisite control over the location, extent, and duration of an inflammatory response. In the lung, CS and HS GAGs bind the neutrophil chemokine CXCL8 (IL-8), controlling its localization and promoting its retention and dimerization (Frevert et al., 2002; Frevert et al., 2003). This interaction favors neutrophil infiltration to sites of injury or inflammation. CD44v3 – a CD44 variant with an HS side chain – is expressed on endothelial cell surfaces, and interacts with CD11b/CD18 integrins on leukocytes to enhance their transmigration into inflamed tissue (Barbour et al., 2003; Zen et al., 2009). Therefore, PG-mediated chemokine presentation and PG binding to leukocyte adhesion receptors promote accumulation of immune cells at inflammatory foci.

After SCI, sulfated PG expression is altered around the lesion. Expression of aggrecan is decreased and its degradation products are detected (Andrews et al., 2012; Lemons et al., 2001). In contrast, neurocan, brevican, and versican increase at the lesion border, beginning at 1 dpi for up to 2 months post-injury (Jones et al., 2003). PGs phosphacan and NG2 also are upregulated by injury (Jones et al., 2002; Levine, 1994; McKeon et al., 1999). The SLRPs decorin and biglycan are strongly upregulated after brain injury and remain elevated for at least 6 months (Stichel et al., 1995), suggesting that they could regulate chronic inflammation after CNS injury.

During inflammation, the types and amounts of specific PG degradation components likely affect progression of the inflammatory response. Chondroitinase-ABC (chABC), a bacterial enzyme that specifically cleaves CS and DS GAG chains from their PG core protein (Prabhakar et al., 2006), limits the biological effects of CS/DSPGs. ChABC can degrade the endogenous chondroitin sulfate CS-A to a disaccharide CSPG product (CSPG-DS), which can modulate inflammation. In a mouse model of experimental autoimmune encephalomyelitis (EAE), intravenous delivery of CSPG-DS led to improved EAE outcomes. Improved recovery was associated with decreased T-cell infiltration and activation (Rolls et al., 2006). In contrast, intravenous administration of intact CS-A prior to EAE symptom onset was detrimental for EAE progression, possibly by driving activation of T-cells towards EAE-propagating Th1 and Th17 cells (Zhou et al., 2010). Therefore, in EAE models, the balance between intact CS-A and its degradation product CSPG-DS has crucial implications for the intensity and duration of inflammation (for review, see (Haylock-Jacobs et al., 2011)).

It is clear that many PGs restrict axon plasticity after SCI (see below); however, whether these PGs impact SCI-induced inflammation remains largely unexplored. Given the diverse functions for PGs, their altered expression/distribution, and their ability to act as DAMPs, PGs likely represent pivotal endogenous mediators of intraspinal inflammation – a function that may ultimately affect the efficiency of axon plasticity and tissue repair.

#### *Plasticity unleashed: Sulfated proteoglycan modulation as a potential SCI treatment*

SCI-induced PG deposition is partially controlled by activation of the transcription factor NF $\kappa$ B in astrocytes. Inhibition of NF $\kappa$ B-mediated signaling in SCI mice, specifically in astrocytes, reduced lesion size and attenuated post-injury elevations of phosphacan and neurocan (Brambilla et al., 2005). Expression of TGF- $\beta$ 2, which drives fibrotic scar formation and neutrophil infiltration, also was decreased in these mice. These data illustrate how the ECM composition can be affected by manipulating inflammatory signaling after SCI.

Sulfated PG regulation of TGF- $\beta$  availability could also impact cellular dynamics and tissue repair after SCI. In the injured spinal cord, TGF- $\beta$ 1 and TGF- $\beta$ 2 are highly expressed by leukocytes and astrocytes (Lagord et al., 2002; McTigue et al., 2000; O'Brien et al., 1994). Treatment of rat brain injury with multiple daily injections of antibodies that bind TGF- $\beta$ 1/ $\beta$ 2 decreased astrogliosis (Moon and Fawcett, 2001). In another study, blockade of endogenous TGF- $\beta$ 2 (but not TGF- $\beta$ 1) using a bioengineered scaffold impregnated with anti- $\beta$ 2 antibodies, limited scar formation after SCI (King et al., 2004). By altering

sulfated PG expression, it might be possible to limit availability or activity of TGF- $\beta$  and limit formation of the inhibitory glial scar.

Most of the work on sulfated PGs after SCI has documented their potent inhibitory effects on axon growth. Bradbury et al. (2002) documented the therapeutic potential of chABC after SCI, showing that the enzyme enhances sensory and corticospinal tract axon regeneration, and improves functional sensory and locomotor recovery. As one of the most effective known treatments in experimental SCI models, chABC is often combined with other promising therapies to synergistically enhance SCI repair (reviewed by Zhao and Fawcett, 2013). Future clinical studies could establish whether chABC is effective after human SCI. Other sulfated PGs can also restrict (Iseki et al., 2002; Ramer et al., 2005) or promote (Davies et al., 2004) axon plasticity. Even intact sulfated PGs can modulate inflammation: macrophages cultured on aggrecan substrate induce axon dieback, an effect that is abolished by chABC-mediated aggrecan digestion (Busch et al., 2009). In addition, in an animal model of demyelination, xyloside-mediated inhibition of CSPG synthesis increased oligodendrocyte number and axon remyelination, suggesting that this could be another mechanism that underlies the efficacy of CSPG-targeting therapies (Lau et al., 2012).

Few studies have addressed how sulfated PGs influence the SCI-induced inflammatory response. Sulfated PGs could have different effects on SCI-induced inflammation and repair over time. When added immediately after injury, xyloside-mediated inhibition of sulfated PG synthesis impaired locomotor recovery; in contrast, delaying xyloside addition until 2 dpi improved functional outcomes, possibly by modifying the inflammatory response (Rolls et al., 2008). In general, sulfated PGs potently elicit peripheral inflammation, so a similar role is expected in the injured CNS. Interactions between sulfated PGs and inflammatory cells in the injured CNS could enhance leukocyte migration and activation, promote glial scar formation, or influence axon plasticity. Future SCI studies should examine inflammation in transgenic mouse models in which specific sulfated PGs are removed (e.g., mice lacking aggrecan, biglycan, or syndecan-4 exist (Echtermeyer et al., 2001; Giamanco et al., 2010; Young et al., 2002)). Since sulfated PGs (and their modifications) can have vastly different effects after SCI, carefully defining the effects of specific sulfated PG variants will be instrumental in designing potential treatments. Conversely, the complexity involved in defining roles of specific PGs could be bypassed altogether by further studying the effects of molecules that inhibit expression of sulfated PGs in the first place (e.g., xyloside).

### Tenascins: Promiscuous proteins weave a complex narrative

The tenascin family of proteins is another key component of the CNS ECM. The mammalian tenascins include tenascin-C, -R, -W, and -X. Each tenascin subunit is composed of an N-terminal assembly domain, variable numbers of EGF and fibronectin type III repeats, and a C-terminal fibrinogen globe (Jones and Jones, 2000). The assembly domain allows for formation of tenascin oligomers (e.g., tenascin-C: hexamer; tenascin-R: dimer or trimer) (Erickson and Inglesias, 1984; Jones and Jones, 2000; Norenberg et al., 1996; Pesheva et al., 1989). The fibronectin repeats endow tenascins with the ability to interact with various extracellular molecules and cell surface receptors. For instance, specific tenascin-C fibronectin repeats bind to heparan sulfates, integrins, HSPGs, or TLR-4 (Midwood and Orend, 2009). Also, tenascins are highly elastic, allowing them to stretch over long distances and bind with multiple ligands (Oberhauser et al., 1998). These flexible tenascin oligomers can anchor and cross-link ECM molecules and cell surface receptors.

#### *Tenascins in the healthy spinal cord*

Of all the tenascins, only tenascin-R and tenascin-C have defined roles in the CNS: whereas tenascin-R is expressed throughout the healthy adult CNS, tenascin-C isoforms are expressed during development

then become downregulated in adults, except in neuro- and gliogenic regions of the brain (Bartsch et al., 1992; Gotz et al., 1997; Joester and Faissner, 1999; Mitrovic et al., 1994). In the healthy adult spinal cord, tenascin-C expression is restricted to motor neurons, ependymal cells, and the pial surface (Zhang et al., 1995).

Tenascin-R has various roles in the healthy CNS. Tenascin-R is expressed by oligodendrocytes and motor neurons and also in perineuronal nets (Galtrey et al., 2008; Pesheva and Probstmeier, 2000). Its binding partners include CSPGs, contactin-1, RPTP- $\beta/\zeta$ , and myelin-associated glycoprotein (Milev et al., 1998; Yang et al., 1999; Zacharias and Rauch, 2006). Through these interactions, tenascin-R has been implicated in axon growth and guidance (Becker et al., 2000; Becker et al., 2004), neuron and oligodendrocyte differentiation (Pesheva et al., 1997), PNN formation/maintenance (Galtrey et al., 2008), and modulation of voltage-gated sodium channels in myelinated axons (Srinivasan et al., 1998).

#### *Tenascins and inflammation: Implications for SCI repair*

Tenascin-C acts as a DAMP, eliciting activation of innate immune cells via by binding to TLR-4 (Goh et al., 2010). This was first demonstrated in a model of arthritis where inflammatory disease symptoms in tenascin-C KO mice resolved rapidly; conversely, tenascin-C injection elicited joint inflammation (Midwood et al., 2009). In macrophages isolated from patients with rheumatoid arthritis, tenascin-C triggers release of inflammatory cytokines in a TLR-4-dependent manner. Tenascin-C:TLR-4 binding can transform macrophages into potentially damaging foam cells (Liu et al., 2012) and can increase MMP-9 expression and transmigration of neutrophils (Kuriyama et al., 2011). TLR-4 stimuli upregulate tenascin-C in macrophages so tenascin-C can act in an autocrine loop to amplify acute inflammation (Goh et al., 2010). Although acute tenascin-C expression is required for proper wound healing (Sumioka et al., 2013), persistent expression can be detrimental; tenascin-C is upregulated in mice with Alzheimer's disease, and its deletion reduces neuropathology and inflammation (Xie et al., 2013). Tenascin-C is an important factor in propagating chronic inflammation and could act in a similar manner after SCI.

In addition to TLR-4, tenascin-C binds to various integrins (Jones et al., 1997; Schnapp et al., 1995; Sriramarao et al., 1993; Yokosaki et al., 1998). On inflammatory cells, these interactions regulate cell adhesion, migration, and activation. Tenascin-C interaction with  $\alpha 5\beta 1$  integrin restricts migration of human monocytes and neutrophils (Loike et al., 2001). Likewise,  $\alpha 9$  integrin activation by tenascin-C triggers macrophage and neutrophil transmigration and cytokine production (Kanayama et al., 2009). Tenascin-C: integrin interactions also promote neurite outgrowth. Cultured chick motor and sensory neurons extend neurites on tenascin-C substrate; this growth is dependent on  $\alpha 8\beta 1$  integrin (Varnum-Finney et al., 1995). Similarly, whereas untreated rat dorsal root ganglion neurons do not extend neurites when plated onto a tenascin-C substrate, neurons engineered to overexpress  $\alpha 9$  integrin exhibit extensive neurite outgrowth in vitro and in vivo (Andrews et al., 2009).

After SCI, de novo synthesis of tenascin-C occurs around the lesion by 3 dpi and its expression persists for at least 30 dpi (Zhang et al., 1997). Tenascin-C is expressed by astrocytes in the lesion border, within the dorsal columns and within the lesion epicenter. Interestingly, astrocytes cultured on tenascin-C express fewer scar-related markers and proliferate less than astrocytes grown on control substrates (Holley et al., 2005), implying that tenascin-C may restrict astrogliosis and scar formation after SCI.

The role of tenascin-R in inflammation has not been studied extensively, likely because tenascin-R expression is restricted to the healthy CNS in adult mammals (Pesheva and Probstmeier, 2000). After SCI, tenascin-R is upregulated around the lesion. Tenascin-R prevents adhesion of activated microglia in vitro and in vivo (Angelov et al., 1998). Also, tenascin-R elicits secretion of cytokines (e.g., TNF-

$\alpha$ ) and growth factors (e.g., brain-derived neurotrophic factor) from cultured microglia (Liao et al., 2005). Further studies must be performed to establish whether the effects of tenascin-R on microglia improve repair, and whether the ECM protein affects other immune cells or astrocytes after SCI.

#### *Tailored tenascin targeting: Potential as an SCI treatment*

Data from different pre-clinical disease models indicate that tenascin-C exacerbates CNS inflammation (Jakovcevski et al., 2013), so tenascin-C might be predicted to propagate inflammation and impair recovery after SCI. However, tenascin-C KO mice show reduced recovery of locomotor function after SCI – an effect attributed to greater corticospinal tract axon dieback and reduced axon sprouting compared to wild-type mice (Chen et al., 2010). In a follow-up study using a model of lumbar spinal cord hemisection injury, global deletion of tenascin-C was associated with enhanced axonal plasticity and growth into the lesion site (Schreiber et al., 2013). The authors concluded that deleting tenascin-C conferred this benefit because of changes in the kinetics and composition of the inflammatory reaction and ECM.

Although global tenascin-C deletion impairs locomotor recovery, the precise mechanisms responsible for these changes have not been determined. Performing complementary gain-of-function experiments in wild-type mice and focused analyses of specific cellular and molecular pathways (e.g., inflammation) in KO mice are still needed. Clearly, the consistent upregulation of tenascin-C after injury and its ability to bind/activate TLRs suggest that it is a candidate for controlling inflammation after SCI. If chronic tenascin-C upregulation after SCI is beneficial for axon growth but activates damaging inflammatory cascades, future experiments could differentially target these processes in space and time, or in specific cell types (e.g., conditional deletion). Moreover, the diverse functional domains of tenascin-C could have cell-specific effects. Delivery of engineered tenascin-C constructs to the site of injury might preserve the beneficial effects of tenascin-C while minimizing those effects that limit recovery after SCI.

#### **Conclusions & implications**

The intimate link between ECM structure and inflammatory activation is exemplified by the enormous changes elicited by SCI. SCI-induced ECM breakdown causes catastrophic destruction of structural meshwork that enables cell survival and functional communication (Fig. 2b). ECM peptides are liberated that influence the subsequent inflammatory response. These peptides alert and provide information to glia and immune cells about the nature and intensity of damage, often through specialized PRRs. Unfortunately, in the injured CNS, many of these ECM alterations serve to amplify inflammatory responses beyond a threshold that leads to a chronic inflammatory state (Fig. 3). Major DAMPs released or expressed after SCI include LMW-HA, tenascin-C, and specific sulfated PG fragments. These drive expression of inflammatory cytokines and matrix modifiers, such as MMPs, which further degrade the ECM and propagate the destructive inflammatory cycle.

By restricting SCI-induced ECM degradation or expression of inflammatory ECM molecules, we may limit secondary damage and provide substrates for axon plasticity. This could involve using treatments that: 1) protect endogenous ECM structural components; 2) degrade components that elicit inflammation into less harmful (or protective) molecules (e.g., chABC-mediated CS-A breakdown to CSPG-DS); 3) provide a physical structure for tissue repair (e.g., addition of immune inert biomaterials); or 4) limit expression of potentially damaging intact ECM molecules (e.g., xyloside). Conversely, treatments that restrict inflammatory reactions after SCI could preserve remaining ECM structure. A more restrained inflammatory response may actually enhance tissue repair. Through targeting these cascades individually or in parallel, we may reduce tissue pathology, increase axon plasticity, and improve functional recovery.

Research on the relationship between ECM and inflammation after SCI is in its infancy. By examining existing data from other disease models, SCI (and CNS) researchers can gain valuable insight that could guide future research efforts. Given the consequences of the ECM-inflammation inter-relationship after SCI, discovering new treatments that alter these interactions could improve SCI repair.

#### **Acknowledgments**

The authors thank Dr. Laura Fonken for her editorial input and Dr. Andrew Sauerbeck for his technical expertise. This work was supported by a Canadian Institutes for Health Research (CIHR) Postdoctoral Fellowship (ADG) and NINDS R01NS072304 and the Ray W. Poppleton Endowment (PGP).

#### **References**

- Agrawal, S.M., Lau, L., Yong, V.W., 2008. MMPs in the central nervous system: where the good guys go bad. *Semin. Cell Dev. Biol.* 19, 42–51.
- Alilain, W.J., Horn, K.P., Hu, H., Dick, T.E., Silver, J., 2011. Functional regeneration of respiratory pathways after spinal cord injury. *Nature* 475, 196–200.
- Andrews, M.R., Czitkovich, S., Dassie, E., Vogelaar, C.F., Faissner, A., Blits, B., Gage, F.H., French-Constant, C., Fawcett, J.W., 2009. Alpha9 integrin promotes neurite outgrowth on tenascin-C and enhances sensory axon regeneration. *J. Neurosci.* 29, 5546–5557.
- Andrews, E.M., Richards, R.J., Yin, F.Q., Viapiano, M.S., Jakeman, L.B., 2012. Alterations in chondroitin sulfate proteoglycan expression occur both at and far from the site of spinal contusion injury. *Exp. Neurol.* 235, 174–187.
- Angelov, D.N., Walther, M., Streppel, M., Guntinas-Lichius, O., Neiss, W.F., Probstmeier, R., Pesheva, P., 1998. Tenascin-R is antiadhesive for activated microglia that induce downregulation of the protein after peripheral nerve injury: a new role in neuronal protection. *J. Neurosci.* 18, 6218–6229.
- Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C.B., Seed, B., 1990. CD44 is the principal cell surface receptor for hyaluronate. *Cell* 61, 1303–1313.
- Aspberg, A., Miura, R., Bourdoulous, S., Shimomura, M., Heinegard, D., Schachner, M., Ruoslahti, E., Yamaguchi, Y., 1997. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein–protein interactions independent of carbohydrate moiety. *Proc. Natl. Acad. Sci. U. S. A.* 94, 10116–10121.
- Austin, J.W., Gilchrist, C., Fehlings, M.G., 2012. High molecular weight hyaluronan reduces lipopolysaccharide mediated microglial activation. *J. Neurochem.* 122, 344–355.
- Barbour, A.P., Reeder, J.A., Walsh, M.D., Fawcett, J., Antalis, T.M., Gotley, D.C., 2003. Expression of the CD44v2–10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3. *Cancer Res.* 63, 887–892.
- Bartholdi, D., Schwab, M.E., 1997. Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. *Eur. J. Neurosci.* 9, 1422–1438.
- Bartsch, S., Bartsch, U., Dorries, U., Faissner, A., Weller, A., Ekblom, P., Schachner, M., 1992. Expression of tenascin in the developing and adult cerebellar cortex. *J. Neurosci.* 12, 736–749.
- Beck, K.D., Nguyen, H.X., Galvan, M.D., Salazar, D.L., Woodruff, T.M., Anderson, A.J., 2010. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. *Brain* 133, 433–447.
- Becker, T., Anliker, B., Becker, C.G., Taylor, J., Schachner, M., Meyer, R.L., Bartsch, U., 2000. Tenascin-R inhibits regrowth of optic fibers in vitro and persists in the optic nerve of mice after injury. *Glia* 29, 330–346.
- Becker, C.G., Schweitzer, J., Feldner, J., Schachner, M., Becker, T., 2004. Tenascin-R as a repellent guidance molecule for newly growing and regenerating optic axons in adult zebrafish. *Mol. Cell. Neurosci.* 26, 376–389.
- Beril, G.H., Solaroglu, I., Okutan, O., Cimen, B., Kaptanoglu, E., Palaoglu, S., 2007. Metoprolol treatment decreases tissue myeloperoxidase activity after spinal cord injury in rats. *J. Clin. Neurosci.* 14, 138–142.
- Bianchi, M.E., 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. *J. Leukoc. Biol.* 81, 1–5.
- Biglami, A., Asher, R., 1992. Some observations on the localization of hyaluronic acid in adult, newborn and embryonal rat brain. *Int. J. Dev. Neurosci.* 10, 45–57.
- Biglami, A., Hosley, M., Dahl, D., 1993. Hyaluronic acid and hyaluronic acid-binding proteins in brain extracellular matrix. *Anat. Embryol. (Berl)* 188, 419–433.
- Blight, A.R., 1994. Effects of silica on the outcome from experimental spinal cord injury: implication of macrophages in secondary tissue damage. *Neuroscience* 60, 263–273.
- Bocian, C., Urbanowitz, A.K., Owens, R.T., Iozzo, R.V., Gotte, M., Seidler, D.G., 2013. Decorin potentiates interferon-gamma activity in a model of allergic inflammation. *J. Biol. Chem.* 288, 12699–12711.
- Bradbury, E.J., Moon, L.D., Popat, R.J., King, V.R., Bennett, G.S., Patel, P.N., Fawcett, J.W., McMahon, S.B., 2002. Chondroitinase ABC promotes functional recovery after spinal cord injury. *Nature* 416, 636–640.
- Brambilla, R., Bracchi-Ricard, V., Hu, W.H., Frydel, B., Bramwell, A., Karmally, S., Green, E.J., Betha, J.R., 2005. Inhibition of astroglial nuclear factor kappaB



- reduces inflammation and improves functional recovery after spinal cord injury. *J. Exp. Med.* 202, 145–156.
- Brown, K.L., Maiti, A., Johnson, P., 2001. Role of sulfation in CD44-mediated hyaluronan binding induced by inflammatory mediators in human CD14(+) peripheral blood monocytes. *J. Immunol.* 167, 5367–5374.
- Brule, S., Charnaux, N., Sutton, A., Ledoux, D., Chaigneau, T., Saffar, L., Gattego, L., 2006. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. *Glycobiology* 16, 488–501.
- Busch, S.A., Horn, K.P., Silver, D.J., Silver, J., 2009. Overcoming macrophage-mediated axonal dieback following CNS injury. *J. Neurosci.* 29, 9967–9976.
- Chen, J., Joon, L.H., Jakovcsevski, I., Shah, R., Bhagat, N., Loers, G., Liu, H.Y., Meiners, S., Taschenberger, G., Kugler, S., Irintchev, A., Schachner, M., 2010. The extracellular matrix glycoprotein tenascin-C is beneficial for spinal cord regeneration. *Mol. Ther.* 18, 1769–1777.
- Collins, S.L., Black, K.E., Chan-Li, Y., Ahn, Y.H., Cole, P.A., Powell, J.D., Horton, M.R., 2011. Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2a receptor. *Am. J. Respir. Cell Mol. Biol.* 45, 675–683.
- Davies, J.E., Tang, X., Denning, J.W., Archibald, S.J., Davies, S.J., 2004. Decorin suppresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries. *Eur. J. Neurosci.* 19, 1226–1242.
- Diegelmann, R.F., Evans, M.C., 2004. Wound healing: an overview of acute, fibrotic and delayed healing. *Front. Biosci.* 9, 283–289.
- Ding, Q., Wu, Z., Guo, Y., Zhao, C., Jia, Y., Kong, F., Chen, B., Wang, H., Xiong, S., Que, H., Jing, S., Liu, S., 2006. Proteome analysis of up-regulated proteins in the rat spinal cord induced by transection injury. *Proteomics* 6, 505–518.
- Dityatev, A., Schachner, M., Sonderegger, P., 2010. The dual role of the extracellular matrix in synaptic plasticity and homeostasis. *Nat. Rev. Neurosci.* 11, 735–746.
- Echtermeyer, F., Streit, M., Wilcox-Adelman, S., Saoncella, S., Denhez, F., Detmar, M., Goetinck, P., 2001. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. *J. Clin. Invest.* 107, R9–R14.
- Eggli, P.S., Lucocq, J., Ott, P., Graber, W., van der Zypen, E., 1992. Ultrastructural localization of hyaluronan in myelin sheaths of the rat central and rat and human peripheral nervous systems using hyaluronan-binding protein-gold and link protein-gold. *Neuroscience* 48, 737–744.
- Eng, L.F., Lee, Y.L., 2003. Response of chemokine antagonists to inflammation in injured spinal cord. *Neurochem. Res.* 28, 95–100.
- Erickson, H.P., Inglesias, J.L., 1984. A six-armed oligomer isolated from cell surface fibronectin preparations. *Nature* 311, 267–269.
- Erridge, C., 2010. Endogenous ligands of TLR2 and TLR4: agonists or assistants? *J. Leukoc. Biol.* 87, 989–999.
- Esser, P.R., Wolffe, U., Durr, C., von Loewenich, F.D., Schempp, C.M., Freudenberg, M.A., Jakob, T., Martin, S.F., 2012. Contact sensitizers induce skin inflammation via ROS production and hyaluronic acid degradation. *PLoS One* 7, e41340.
- Faulkner, J.R., Herrmann, J.E., Woo, M.J., Tansey, K.E., Doan, N.B., Sofroniew, M.V., 2004. Reactive astrocytes protect tissue and preserve function after spinal cord injury. *J. Neurosci.* 24, 2143–2155.
- Fleming, J.C., Norenberg, M.D., Ramsay, D.A., Dekaban, G.A., Marcillo, A.E., Saenz, A.D., Pasquale-Styles, M., Dietrich, W.D., Weaver, L.C., 2006. The cellular inflammatory response in human spinal cords after injury. *Brain* 129, 3249–3269.
- Frevort, C.W., Goodman, R.B., Kinsella, M.G., Kajikawa, O., Ballman, K., Clark-Lewis, I., Proudfoot, A.E., Wells, T.N., Martin, T.R., 2002. Tissue-specific mechanisms control the retention of IL-8 in lungs and skin. *J. Immunol.* 168, 3550–3556.
- Frevort, C.W., Kinsella, M.G., Vathanaprida, C., Goodman, R.B., Baskin, D.G., Proudfoot, A., Wells, T.N., Wight, T.N., Martin, T.R., 2003. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. *Am. J. Respir. Cell Mol. Biol.* 28, 464–472.
- Galtrey, C.M., Kwok, J.C., Carulli, D., Rhodes, K.E., Fawcett, J.W., 2008. Distribution and synthesis of extracellular matrix proteoglycans, hyaluronan, link proteins and tenascin-R in the rat spinal cord. *Eur. J. Neurosci.* 27, 1373–1390.
- Garcia-Alias, G., Fawcett, J.W., 2012. Training and anti-CSPG combination therapy for spinal cord injury. *Exp. Neurol.* 235, 26–32.
- Giamanco, K.A., Morawski, M., Matthews, R.T., 2010. Perineuronal net formation and structure in aggrecan knockout mice. *Neuroscience* 170, 1314–1327.
- Gill, S., Wight, T.N., Frevort, C.W., 2010. Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection. *Anat. Rec.* 293, 968–981.
- Giuliani, D., Robertson, C., 1990. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. *Ann. Neurol.* 27, 33–42.
- Goh, F.G., Piccinini, A.M., Krausgruber, T., Udalo, I.A., Midwood, K.S., 2010. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. *J. Immunol.* 184, 2655–2662.
- Gotte, M., 2003. Syndecans in inflammation. *FASEB J.* 17, 575–591.
- Gotz, M., Bolz, J., Joester, A., Faissner, A., 1997. Tenascin-C synthesis and influence on axonal growth during rat cortical development. *Eur. J. Neurosci.* 9, 496–506.
- Gris, D., Marsh, D.R., Oatway, M.A., Chen, Y., Hamilton, E.F., Dekaban, G.A., Weaver, L.C., 2004. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. *J. Neurosci.* 24, 4043–4051.
- Gupta, D., Tator, C.H., Shoichet, M.S., 2006. Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. *Biomaterials* 27, 2370–2379.
- Haddock, G., Cross, A.K., Allan, S., Sharrack, B., Callaghan, J., Bunning, R.A., Buttler, D.J., Woodroffe, M.N., 2007. Brevican and phosphacan expression and localization following transient middle cerebral artery occlusion in the rat. *Biochem. Soc. Trans.* 35, 692–694.
- Hagino, S., Iseki, K., Mori, T., Zhang, Y., Hikake, T., Yokoya, S., Takeuchi, M., Hasimoto, H., Kikuchi, S., Wanaka, A., 2003. Slit and glypican-1 mRNAs are coexpressed in the reactive astrocytes of the injured adult brain. *Glia* 42, 130–138.
- Hansen, C.N., Fisher, L.C., Deibert, R.J., Jakeman, L.B., Zhang, H., Noble-Haesslein, L., White, S., Basso, D.M., 2013. Elevated MMP-9 in the lumbar cord early after thoracic spinal cord injury impedes motor relearning in mice. *J. Neurosci.* 33, 13101–13111.
- Hardingham, T.E., Fosang, A.J., 1992. Proteoglycans: many forms and many functions. *FASEB J.* 6, 861–870.
- Hardingham, T.E., Muir, H., 1972. The specific interaction of hyaluronic acid with cartilage proteoglycans. *Biochim. Biophys. Acta* 279, 401–405.
- Hardwick, C., Hoare, K., Owens, R., Hohn, H.P., Hook, M., Moore, D., Cripps, V., Austen, L., Nance, D.M., Turley, E.A., 1992. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. *J. Cell Biol.* 117, 1343–1350.
- Haylock-Jacobs, S., Keough, M.B., Lau, L., Yong, V.W., 2011. Chondroitin sulphate proteoglycans: extracellular matrix proteins that regulate immunity of the central nervous system. *Autoimmun. Rev.* 10, 766–772.
- Hildebrand, A., Romaris, M., Rasmussen, L.M., Heinegard, D., Twardzik, D.R., Border, W.A., Ruoslahti, E., 1994. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. *Biochem. J.* 302 (Pt 2), 527–534.
- Holley, J.E., Gveric, D., Whatmore, J.L., Gutowski, N.J., 2005. Tenascin C induces a quiescent phenotype in cultured adult human astrocytes. *Glia* 52, 53–58.
- Hollingsworth, J.W., Li, Z., Brass, D.M., Garantzios, S., Timberlake, S.H., Kim, A., Hossain, I., Savani, R.C., Schwartz, D.A., 2007. CD44 regulates macrophage recruitment to the lung in lipopolysaccharide-induced airway disease. *Am. J. Respir. Cell Mol. Biol.* 37, 248–253.
- Hrabarova, E., Juranek, I., Soltes, L., 2011. Pro-oxidative effect of peroxynitrite regarding biological systems: a special focus on high-molar-mass hyaluronan degradation. *Gen. Physiol. Biophys.* 30, 223–238.
- Hsu, J.Y., Bourguignon, L.Y., Adams, C.M., Peyrollier, K., Zhang, H., Fandel, T., Cun, C.L., Werb, Z., Noble-Haesslein, L.J., 2008. Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. *J. Neurosci.* 28, 13467–13477.
- Hynes, R.O., Naba, A., 2012. Overview of the matrisome—an inventory of extracellular matrix constituents and functions. *Cold Spring Harb. Perspect. Biol.* 4, a004903.
- Iozzo, R.V., 1998. Matrix proteoglycans: from molecular design to cellular function. *Annu. Rev. Biochem.* 67, 609–652.
- Iseki, K., Hagino, S., Mori, T., Zhang, Y., Yokoya, S., Takaki, H., Tase, C., Murakawa, M., Wanaka, A., 2002. Increased syndecan expression by pleiotrophin and FGF receptor-expressing astrocytes in injured brain tissue. *Glia* 39, 1–9.
- Jakovcsevski, I., Miljkovic, D., Schachner, M., Andjus, P.R., 2013. Tenascin and inflammation in disorders of the nervous system. *Amino Acids* 44, 1115–1127.
- Jiang, D., Liang, J., Fan, J., Yu, S., Chen, S., Luo, Y., Prestwich, G.D., Mascarenhas, M.M., Garg, H.G., Quinn, D.A., Homer, R.J., Goldstein, D.R., Bucala, R., Lee, P.J., Medzhitov, R., Noble, P.W., 2005. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. *Nat. Med.* 11, 1173–1179.
- Jiang, D., Liang, J., Noble, P.W., 2007. Hyaluronan in tissue injury and repair. *Annu. Rev. Cell Dev. Biol.* 23, 435–461.
- Joester, A., Faissner, A., 1999. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system. *J. Biol. Chem.* 274, 17144–17151.
- Johnson, G.B., Brunn, G.J., Platt, J.L., 2004. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. *J. Immunol.* 172, 20–24.
- Jones, F.S., Jones, P.L., 2000. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. *Dev. Dyn.* 218, 235–259.
- Jones, P.L., Crack, J., Rabinovitch, M., 1997. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. *J. Cell Biol.* 139, 279–293.
- Jones, L.L., Yamaguchi, Y., Stallcup, W.B., Tuszynski, M.H., 2002. NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. *J. Neurosci.* 22, 2792–2803.
- Jones, L.L., Margolis, R.U., Tuszynski, M.H., 2003. The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. *Exp. Neurol.* 182, 399–411.
- Kanayama, M., Kurotaki, D., Morimoto, J., Asano, T., Matsui, Y., Nakayama, Y., Saito, Y., Ito, K., Kimura, C., Iwasaki, N., Suzuki, K., Harada, T., Li, H.M., Uehara, J., Miyazaki, T., Minami, A., Kon, S., Ueda, T., 2009. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. *J. Immunol.* 182, 8015–8025.
- Kawana, H., Karaki, H., Higashi, M., Miyazaki, M., Hilberg, F., Kitagawa, M., Harigaya, K., 2008. CD44 suppresses TLR-mediated inflammation. *J. Immunol.* 180, 4235–4245.
- Khaing, Z.Z., Millman, B.D., Vanscoy, J.E., Seidltis, S.K., Grill, R.J., Schmidt, C.E., 2011. High molecular weight hyaluronic acid limits astrocyte activation and scar formation after spinal cord injury. *J. Neural Eng.* 8, 046033.
- Khan, A.I., Kerfoot, S.M., Heit, B., Liu, L., Andonegui, G., Ruffell, B., Johnson, P., Kubes, P., 2004. Role of CD44 and hyaluronan in neutrophil recruitment. *J. Immunol.* 173, 7594–7601.
- Kigerl, K.A., de Rivero Vaccari, J.P., Dietrich, W.D., Popovich, P.G., Keane, R.W., 2014. Pattern recognition receptors and central nervous system repair. *Exp. Neurol.* 258, 5–16 (in this issue).
- Kigerl, K.A., McLaughly, V.M., Popovich, P.G., 2006. Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury. *J. Comp. Neurol.* 494, 578–594.
- Kigerl, K.A., Lai, W., Rivest, S., Hart, R.P., Satoskar, A.R., Popovich, P.G., 2007. Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. *J. Neurochem.* 102, 37–50.

- Kigerl, K.A., Gensel, J.C., Ankeny, D.P., Alexander, J.K., Donnelly, D.J., Popovich, P.G., 2009. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. *J. Neurosci.* 29, 13435–13444.
- Kim, S., Takahashi, H., Lin, W.W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.L., Karin, M., 2009. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. *Nature* 457, 102–106.
- King, V.R., Phillips, J.B., Brown, R.A., Priestley, J.V., 2004. The effects of treatment with antibodies to transforming growth factor beta1 and beta2 following spinal cord damage in the adult rat. *Neuroscience* 126, 173–183.
- Knudson, C.B., Knudson, W., 1993. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. *FASEB J.* 7, 1233–1241.
- Kolb, M., Margetts, P.J., Sime, P.J., Gauldie, J., 2001. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 280, L1327–L1334.
- Kuriyama, N., Duarte, S., Hamada, T., Busuttill, R.W., Coito, A.J., 2011. Tenascin-C: a novel mediator of hepatic ischemia and reperfusion injury. *Hepatology* 54, 2125–2136.
- Kwok, J.C., Afshari, F., Garcia-alias, G., Fawcett, J.W., 2008. Proteoglycans in the central nervous system: plasticity, regeneration and their stimulation with chondroitinase ABC. *Restor. Neurol. Neurosci.* 26, 131–145.
- Lagord, C., Berry, M., Logan, A., 2002. Expression of TGFbeta2 but not TGFbeta1 correlates with the deposition of scar tissue in the lesioned spinal cord. *Mol. Cell. Neurosci.* 20, 69–92.
- Lau, L.W., Keough, M.B., Haylock-Jacobs, S., Cua, R., Doring, A., Sloka, S., Stirling, D.P., Rivest, S., Yong, V.W., 2012. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. *Ann. Neurol.* 72, 419–432.
- Lau, L.W., Cua, R., Keough, M.B., Haylock-Jacobs, S., Yong, V.W., 2013. Pathophysiology of the brain extracellular matrix: a new target for remyelination. *Nat. Rev. Neurosci.* 14, 722–729.
- Laurent, T.C., Fraser, J.R., 1992. Hyaluronan. *FASEB J.* 6, 2397–2404.
- Lemons, M.L., Sandy, J.D., Anderson, D.K., Howland, D.R., 2001. Intact aggrecan and fragments generated by both aggrecanase and metalloproteinase-like activities are present in the developing and adult rat spinal cord and their relative abundance is altered by injury. *J. Neurosci.* 21, 4772–4781.
- Lemons, M.L., Sandy, J.D., Anderson, D.K., Howland, D.R., 2003. Intact aggrecan and chondroitin sulfate-depleted aggrecan core glycoprotein inhibit axon growth in the adult rat spinal cord. *Exp. Neurol.* 184, 981–990.
- Levesque, M.C., Haynes, B.F., 1997. Cytokine induction of the ability of human monocyte CD44 to bind hyaluronan is mediated primarily by TNF-alpha and is inhibited by IL-4 and IL-13. *J. Immunol.* 159, 6184–6194.
- Levine, J.M., 1994. Increased expression of the NG2 chondroitin-sulfate proteoglycan after brain injury. *J. Neurosci.* 14, 4716–4730.
- Liang, J., Jiang, D., Griffith, J., Yu, S., Fan, J., Zhao, X., Bucala, R., Noble, P.W., 2007. CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages. *J. Immunol.* 178, 2469–2475.
- Liao, H., Bu, W.Y., Wang, T.H., Ahmed, S., Xiao, Z.C., 2005. Tenascin-R plays a role in neuroprotection via its distinct domains that coordinate to modulate the microglia function. *J. Biol. Chem.* 280, 8316–8323.
- Liu, R., He, Y., Li, B., Liu, J., Ren, Y., Han, W., Wang, X., Zhang, L., 2012. Tenascin-C produced by oxidized LDL-stimulated macrophages increases foam cell formation through Toll-like receptor-4. *Mol. Cells* 34, 35–41.
- Loike, J.D., Cao, L., Budhu, S., Hoffman, S., Silverstein, S.C., 2001. Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins. *J. Immunol.* 166, 7534–7542.
- Malemud, C.J., 2006. Matrix metalloproteinases (MMPs) in health and disease: an overview. *Front. Biosci.* 11, 1696–1701.
- McCourt, P.A., Ek, B., Forsberg, N., Gustafson, S., 1994. Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. *J. Biol. Chem.* 269, 30081–30084.
- McKee, C.M., Penno, M.B., Cowman, M., Burdick, M.D., Strieter, R.M., Bao, C., Noble, P.W., 1996. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. *J. Clin. Invest.* 98, 2403–2413.
- McKeon, R.J., Schreiber, R.C., Rudge, J.S., Silver, J., 1991. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. *J. Neurosci.* 11, 3398–3411.
- McKeon, R.J., Jurynec, M.J., Buck, C.R., 1999. The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. *J. Neurosci.* 19, 10778–10788.
- McTigue, D.M., Popovich, P.G., Morgan, T.E., Stokes, B.T., 2000. Localization of transforming growth factor-beta1 and receptor mRNA after experimental spinal cord injury. *Exp. Neurol.* 163, 220–230.
- Melin, F.C., Morgelin, M., Vadstrup, K., Heinegard, D., Aspberg, A., Blom, A.M., 2013. The C-type lectin of the aggrecan G3 domain activates complement. *PLoS One* 8, e61407.
- Midwood, K.S., Orend, G., 2009. The role of tenascin-C in tissue injury and tumorigenesis. *J. Cell Commun. Signal.* 3, 287–310.
- Midwood, K., Sacre, S., Piccinini, A.M., Inglis, J., Trebaul, A., Chan, E., Drexler, S., Sofat, N., Kashiwagi, M., Orend, G., Brennan, F., Foxwell, B., 2009. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. *Nat. Med.* 15, 774–780.
- Milev, P., Chiba, A., Haring, M., Rauvala, H., Schachner, M., Ranscht, B., Margolis, R.K., Margolis, R.U., 1998. High affinity binding and overlapping localization of neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule. *J. Biol. Chem.* 273, 6998–7005.
- Mitrovic, N., Dorries, U., Schachner, M., 1994. Expression of the extracellular matrix glycoprotein tenascin in the somatosensory cortex of the mouse during postnatal development: an immunocytochemical and in situ hybridization analysis. *J. Neurocytol.* 23, 364–378.
- Moon, L.D., Fawcett, J.W., 2001. Reduction in CNS scar formation without concomitant increase in axon regeneration following treatment of adult rat brain with a combination of antibodies to TGFbeta1 and beta2. *Eur. J. Neurosci.* 14, 1667–1677.
- Moon, C., Heo, S., Sim, K.B., Shin, T., 2004. Upregulation of CD44 expression in the spinal cords of rats with clip compression injury. *Neurosci. Lett.* 367, 133–136.
- Moreth, K., Iozzo, R.V., Schaefer, L., 2012. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. *Cell Cycle* 11, 2084–2091.
- Mothe, A.J., Tam, R.Y., Zahir, T., Tator, C.H., Shoichet, M.S., 2013. Repair of the injured spinal cord by transplantation of neural stem cells in a hyaluronan-based hydrogel. *Biomaterials* 34, 3775–3783.
- Muto, J., Yamasaki, K., Taylor, K.R., Gallo, R.L., 2009. Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS. *Mol. Immunol.* 47, 449–456.
- Nathan, C., Ding, A., 2010. Nonresolving inflammation. *Cell* 140, 871–882.
- Noble, L.J., Wrathall, J.R., 1989. Distribution and time course of protein extravasation in the rat spinal cord after contusive injury. *Brain Res.* 482, 57–66.
- Noble, L.J., Donovan, F., Igarashi, T., Goussev, S., Werb, Z., 2002. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. *J. Neurosci.* 22, 7526–7535.
- Norenberg, U., Hubert, M., Rathjen, F.G., 1996. Structural and functional characterization of tenascin-R (restrictin), an extracellular matrix glycoprotein of glial cells and neurons. *Int. J. Dev. Neurosci.* 14, 217–231.
- Oberhauser, A.F., Marszalek, P.E., Erickson, H.P., Fernandez, J.M., 1998. The molecular elasticity of the extracellular matrix protein tenascin. *Nature* 393, 181–185.
- O'Brien, M.F., Lenke, L.G., Lou, J., Bridwell, K.H., Joyce, M.E., 1994. Astrocyte response and transforming growth factor-beta localization in acute spinal cord injury. *Spine* 19, 2321–2329 (Phila Pa 1976.).
- Pajoohesh-Ganji, A., Byrnes, K.R., 2011. Novel neuroinflammatory targets in the chronically injured spinal cord. *Neurotherapeutics* 8, 195–205.
- Parish, C.R., 2006. The role of heparan sulphate in inflammation. *Nat. Rev. Immunol.* 6, 633–643.
- Parks, W.C., Wilson, C.L., Lopez-Boado, Y.S., 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat. Rev. Immunol.* 4, 617–629.
- Pesheva, P., Probstmeier, R., 2000. The yin and yang of tenascin-R in CNS development and pathology. *Prog. Neurobiol.* 61, 465–493.
- Pesheva, P., Spiess, E., Schachner, M., 1989. J1-160 and J1-180 are oligodendrocyte-secreted nonpermissive substrates for cell adhesion. *J. Cell Biol.* 109, 1765–1778.
- Pesheva, P., Gloor, S., Schachner, M., Probstmeier, R., 1997. Tenascin-R is an intrinsic autocrine factor for oligodendrocyte differentiation and promotes cell adhesion by a sulfatide-mediated mechanism. *J. Neurosci.* 17, 4642–4651.
- Piccinini, A.M., Midwood, K.S., 2010. DAMPening inflammation by modulating TLR signaling. *Mediat. Inflamm.* 2010.
- Pineau, I., Sun, L., Bastien, D., Lacroix, S., 2010. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. *Brain Behav. Immun.* 24, 540–553.
- Popovich, P.G., Longbrake, E.E., 2008. Can the immune system be harnessed to repair the CNS? *Nat. Rev. Neurosci.* 9, 481–493.
- Popovich, P.G., Horner, P.J., Mullin, B.B., Stokes, B.T., 1996. A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. *Exp. Neurol.* 142, 258–275.
- Popovich, P.G., Wei, P., Stokes, B.T., 1997. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. *J. Comp. Neurol.* 377, 443–464.
- Popovich, P.G., Guan, Z., Wei, P., Huitinga, I., van, R.N., Stokes, B.T., 1999. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. *Exp. Neurol.* 158, 351–365.
- Prabhakar, V., Capila, I., Raman, R., Srinivasan, A., Bosques, C.J., Pojasek, K., Wruck, M.A., Sasisekharan, R., 2006. The catalytic machinery of chondroitinase ABC I utilizes a calcium coordination strategy to optimally process dermatan sulfate. *Biochemistry* 45, 11130–11139.
- Properzi, F., Lin, R., Kwok, J., Naidu, M., van Kuppevelt, T.H., Ten Dam, G.B., Camargo, L.M., Raha-Chowdhury, R., Furukawa, Y., Mikami, T., Sugahara, K., Fawcett, J.W., 2008. Heparan sulphate proteoglycans in glia and in the normal and injured CNS: expression of sulphotransferases and changes in sulphation. *Eur. J. Neurosci.* 27, 593–604.
- Pruss, H., Kopp, M.A., Brommer, B., Gatzemeier, N., Laginha, I., Dirnagl, U., Schwab, J.M., 2011. Non-resolving aspects of acute inflammation after spinal cord injury (SCI): indices and resolution plateau. *Brain Pathol.* 21, 652–660.
- Ramer, L.M., Ramer, M.S., Steeves, J.D., 2005. Setting the stage for functional repair of spinal cord injuries: a cast of thousands. *Spinal Cord* 43, 134–161.
- Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G.J., Yoles, E., Fraidakis, M., Solomon, A., Gepstein, R., Katz, A., Belkin, M., Hadani, M., Schwartz, M., 1998. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. *Nat. Med.* 4, 814–821.
- Rauch, U., 2004. Extracellular matrix components associated with remodeling processes in brain. *Cell. Mol. Life Sci.* 61, 2031–2045.
- Rauch, U., 2007. Brain matrix: structure, turnover and necessity. *Biochem. Soc. Trans.* 35, 656–660.
- Rolls, A., Cahalon, L., Bakalash, S., Avidan, H., Lider, O., Schwartz, M., 2006. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. *FASEB J.* 20, 547–549.

- Rolls, A., Shechter, R., London, A., Segev, Y., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., Schwartz, M., 2008. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. *PLoS Med.* 5, e171.
- Schaefer, L., Iozzo, R.V., 2008. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. *J. Biol. Chem.* 283, 21305–21309.
- Schaefer, L., Schaefer, R.M., 2010. Proteoglycans: from structural compounds to signaling molecules. *Cell Tissue Res.* 339, 237–246.
- Schaefer, L., Babelova, A., Kiss, E., Hausser, H.J., Baliova, M., Krzyzankova, M., Marsche, G., Young, M.F., Mihalik, D., Gotte, M., Malle, E., Schaefer, R.M., Grone, H.J., 2005. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. *J. Clin. Invest.* 115, 2223–2233.
- Schnapp, L.M., Hatch, N., Ramos, D.M., Klimanskaya, I.V., Sheppard, D., Pytela, R., 1995. The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin. *J. Biol. Chem.* 270, 23196–23202.
- Schnell, L., Fearn, S., Klassen, H., Schwab, M.E., Perry, V.H., 1999. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. *Eur. J. Neurosci.* 11, 3648–3658.
- Schreiber, J., Schachner, M., Schumacher, U., Lorke, D.E., 2013. Extracellular matrix alterations, accelerated leukocyte infiltration and enhanced axonal sprouting after spinal cord hemisection in tenascin-C-deficient mice. *Acta Histochem.* 115, 865–878.
- Shechter, R., Schwartz, M., 2013. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if' but 'how'. *J. Pathol.* 229, 332–346.
- Simard, J.M., Tsybalyuk, O., Ivanov, A., Ivanova, S., Bhatta, S., Geng, Z., Woo, S.K., Gerzanich, V., 2007. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. *J. Clin. Invest.* 117, 2105–2113.
- Simard, J.M., Woo, S.K., Norenberg, M.D., Tosun, C., Chen, Z., Ivanova, S., Tsybalyuk, O., Bryan, J., Landsman, D., Gerzanich, V., 2010. Brief suppression of Abc8 prevents autodestruction of spinal cord after trauma. *Sci. Transl. Med.* 2, 28ra29.
- Siri, A., Knauper, V., Veirana, N., Caocci, F., Murphy, G., Zardi, L., 1995. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. *J. Biol. Chem.* 270, 8650–8654.
- Srinivasan, J., Schachner, M., Catterall, W.A., 1998. Interaction of voltage-gated sodium channels with the extracellular matrix molecules tenascin-C and tenascin-R. *Proc. Natl. Acad. Sci. U. S. A.* 95, 15753–15757.
- Sriramarao, P., Mendler, M., Bourdon, M.A., 1993. Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. *J. Cell Sci.* 105 (Pt 4), 1001–1012.
- Stichel, C.C., Kappler, J., Junghans, U., Koops, A., Kresse, H., Muller, H.W., 1995. Differential expression of the small chondroitin/dermatan sulfate proteoglycans decorin and biglycan after injury of the adult rat brain. *Brain Res.* 704, 263–274.
- Stirling, D.P., Yong, V.W., 2008. Dynamics of the inflammatory response after murine spinal cord injury revealed by flow cytometry. *J. Neurosci. Res.* 86, 1944–1958.
- Stirling, D.P., Liu, S., Kubes, P., Yong, V.W., 2009. Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. *J. Neurosci.* 29, 753–764.
- Struve, J., Maher, P.C., Li, Y.Q., Kinney, S., Fehlings, M.G., Kuntz, C., Sherman, L.S., 2005. Disruption of the hyaluronan-based extracellular matrix in spinal cord promotes astrocyte proliferation. *Glia* 52, 16–24.
- Sugahara, K., Mikami, T., 2007. Chondroitin/dermatan sulfate in the central nervous system. *Curr. Opin. Struct. Biol.* 17, 536–545.
- Sugahara, K.N., Murai, T., Nishinakamura, H., Kawashima, H., Saya, H., Miyasaka, M., 2003. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. *J. Biol. Chem.* 278, 32259–32265.
- Sumioka, T., Kitano, A., Flanders, K.C., Okada, Y., Yamanaka, O., Fujita, N., Iwanishi, H., Kao, W.W., Saika, S., 2013. Impaired cornea wound healing in a tenascin C-deficient mouse model. *Lab. Invest.* 93, 207–217.
- Tammi, M.I., Day, A.J., Turley, E.A., 2002. Hyaluronan and homeostasis: a balancing act. *J. Biol. Chem.* 277, 4581–4584.
- Tang, X., Davies, J.E., Davies, S.J., 2003. Changes in distribution, cell associations, and protein expression levels of NG2, neurocan, phosphacan, brevican, versican V2, and tenascin-C during acute to chronic maturation of spinal cord scar tissue. *J. Neurosci. Res.* 71, 427–444.
- Taylor, K.R., Gallo, R.L., 2006. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. *FASEB J.* 20, 9–22.
- Turley, E.A., Noble, P.W., Bourguignon, L.Y., 2002. Signaling properties of hyaluronan receptors. *J. Biol. Chem.* 277, 4589–4592.
- Varnum-Finney, B., Venstrom, K., Muller, U., Kypta, R., Backus, C., Chiquet, M., Reichardt, L.F., 1995. The integrin receptor alpha 8 beta 1 mediates interactions of embryonic chick motor and sensory neurons with tenascin-C. *Neuron* 14, 1213–1222.
- Wang, D., Fawcett, J., 2012. The perineuronal net and the control of CNS plasticity. *Cell Tissue Res.* 349, 147–160.
- Wanner, I.B., Anderson, M.A., Song, B., Levine, J., Fernandez, A., Gray-Thompson, Z., Ao, Y., Sofroniew, M.V., 2013. Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. *J. Neurosci.* 33, 12870–12886.
- Watanabe, K., Yamaguchi, Y., 1996. Molecular identification of a putative human hyaluronan synthase. *J. Biol. Chem.* 271, 22945–22948.
- Weigel, P.H., Hascall, V.C., Tammi, M., 1997. Hyaluronan synthases. *J. Biol. Chem.* 272, 13997–14000.
- Wells, J.E., Rice, T.K., Nuttall, R.K., Edwards, D.R., Zekki, H., Rivest, S., Yong, V.W., 2003. An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. *J. Neurosci.* 23, 10107–10115.
- Wu, Y.J., La Pierre, D.P., Wu, J., Yee, A.J., Yang, B.B., 2005. The interaction of versican with its binding partners. *Cell Res.* 15, 483–494.
- Xie, K., Liu, Y., Hao, W., Walter, S., Penke, B., Hartmann, T., Schachner, M., Fassbender, K., 2013. Tenascin-C deficiency ameliorates Alzheimer's disease-related pathology in mice. *Neurobiol. Aging* 34, 2389–2398.
- Yang, H., Xiao, Z.C., Becker, B., Hillenbrand, R., Rougon, G., Schachner, M., 1999. Role for myelin-associated glycoprotein as a functional tenascin-R receptor. *J. Neurosci. Res.* 55, 687–701.
- Yokosaki, Y., Matsuura, N., Higashiyama, S., Murakami, I., Obara, M., Yamakido, M., Shigetou, N., Chen, J., Sheppard, D., 1998. Identification of the ligand binding site for the integrin alpha9 beta1 in the third fibronectin type III repeat of tenascin-C. *J. Biol. Chem.* 273, 11423–11428.
- Yong, V.W., 2005. Metalloproteinases: mediators of pathology and regeneration in the CNS. *Nat. Rev. Neurosci.* 6, 931–944.
- Yong, N., Guoping, C., 2008. Upregulation of matrix metalloproteinase-9 dependent on hyaluronan synthesis after sciatic nerve injury. *Neurosci. Lett.* 444, 259–263.
- Yong, V.W., Agrawal, S.M., Stirling, D.P., 2007. Targeting MMPs in acute and chronic neurological conditions. *Neurotherapeutics* 4, 580–589.
- Young, M.F., Bi, Y., Amey, L., Chen, X.D., 2002. Biglycan knockout mice: new models for musculoskeletal diseases. *Glycoconj. J.* 19, 257–262.
- Zacharias, U., Rauch, U., 2006. Competition and cooperation between tenascin-R, lecticans and contactin 1 regulate neurite growth and morphology. *J. Cell Sci.* 119, 3456–3466.
- Zen, K., Liu, D.Q., Li, L.M., Chen, C.X., Guo, Y.L., Ha, B., Chen, X., Zhang, C.Y., Liu, Y., 2009. The heparan sulfate proteoglycan form of epithelial CD44v3 serves as a CD11b/CD18 counter-receptor during polymorphonuclear leukocyte transepithelial migration. *J. Biol. Chem.* 284, 3768–3776.
- Zhang, Y., Anderson, P.N., Campbell, G., Mohajeri, H., Schachner, M., Lieberman, A.R., 1995. Tenascin-C expression by neurons and glial cells in the rat spinal cord: changes during postnatal development and after dorsal root or sciatic nerve injury. *J. Neurocytol.* 24, 585–601.
- Zhang, Y., Winterbottom, J.K., Schachner, M., Lieberman, A.R., Anderson, P.N., 1997. Tenascin-C expression and axonal sprouting following injury to the spinal dorsal columns in the adult rat. *J. Neurosci. Res.* 49, 433–450.
- Zhang, H., Chang, M., Hansen, C.N., Basso, D.M., Noble-Haeusslein, L.J., 2011. Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. *Neurotherapeutics* 8, 206–220.
- Zhao, R.R., Fawcett, J.W., 2013. Combination treatment with chondroitinase ABC in spinal cord injury—breaking the barrier. *Neurosci. Bull.* 29, 477–483.
- Zhou, J., Nagarkatti, P., Zhong, Y., Nagarkatti, M., 2010. Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis. *J. Neuroimmunol.* 223, 55–64.